Compare Skybiotech Healt with Similar Stocks
Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 0% and Operating profit at -1.44% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of -999,999.00 times
Flat results in Dec 25
Risky - Not traded in last 10 days
Stock DNA
Garments & Apparels
INR 27 Cr (Micro Cap)
NA (Loss Making)
52
0.00%
0.83
-26.36%
2.96
Total Returns (Price + Dividend) 
Skybiotech Healt for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Skybiotech Healthcare Limited is Rated Strong Sell
Skybiotech Healthcare Limited is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 Dec 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 16 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
Kapil Cotex Ltd Stock Hits 52-Week Low Amid Continued Downtrend
Kapil Cotex Ltd, a player in the Garments & Apparels sector, recorded a fresh 52-week low of Rs.116.45 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial and operational metrics.
Read full news article
Kapil Cotex Ltd Stock Falls to 52-Week Low of Rs.126.45
Kapil Cotex Ltd, a player in the Garments & Apparels sector, has recorded a fresh 52-week low of Rs.126.45 today, marking a significant decline amid persistent downward momentum. The stock’s recent performance reflects ongoing pressures that have weighed on its valuation and market standing.
Read full news article Announcements 
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30-Apr-2026 | Source : BSEFormat of Initial Disclosure to be made by an entity identified as a Large Corporate.
| Sr. No. | Particulars | Details |
| 1 | Name of Company | Skybiotech Healthcare Ltd |
| 2 | CIN NO. | L17100MH1983PLC031114 |
| 3 | Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) | 0.00 |
| 4 | Highest Credit Rating during the previous FY | NA |
| 4a | Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4) | Not Applicable |
| 5 | Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework | BSE |
Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER
EmailId: kapilcotexlimited@yahoo.co.in
Designation: CFO AND DIRECTOR
EmailId: rathiprakashchandra@yahoo.in
Date: 30/04/2026
Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
09-Apr-2026 | Source : BSECertificate under Reg. 74(5) of SEBI (DP) Regulation 2018 received from RTA
Closure of Trading Window
30-Mar-2026 | Source : BSEIntimation of Trading window closure to consider and approve Audited Financials for the Quarter and year ended on 31st March 2026
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Prakashchandra Rathi (45.16%)
Ganesh Shivprasad Lahoti (4.44%)
34.65%
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
YoY Growth in quarter ended Dec 2025 is -61.90% vs 0.00% in Dec 2024
YoY Growth in quarter ended Dec 2025 is -23.08% vs -136.45% in Dec 2024
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024
Growth in half year ended Sep 2025 is 100.00% vs 50.00% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -500.00% vs -100.95% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024
YoY Growth in year ended Mar 2025 is -96.10% vs 15,500.00% in Mar 2024






